Platelet Activation Affecting the Rate of Vascular Access Patency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the case of cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease, there are many studies that the use of antiplatelet agents is very helpful in improving the vascular patency rate, but there are not many studies on the use of antiplatelet agents in the dialysis approach. The basis for use is insufficient. There is a lack of research on whether maintaining a state in which platelet activation is suppressed is helpful in improving dialysis access patency. Therefore, we conducted this study to determine whether the degree of platelet activation affects the patency of vascular access.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Activation Hemodialysis Fistula Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

platelet activation factors

platelet activation factors of subject blood

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 19 years of age or older who are undergoing hemodialysis during renal replacement therapy
* Patients undergoing arteriovenous fistula formation and hemodialysis to the affected area
* Patients who have the ability and willingness to consent to participate in the clinical study, have signed the consent form in accordance with the appropriate procedures, and can visit and participate in the clinical study as planned

Exclusion Criteria

* Patients who failed to start hemodialysis with an arteriovenous fistula within 3 months
* Patients who have had stent implantation or surgery during the study period due to cardiovascular disease
* Patients with severe hepatic impairment
* Patients with coagulopathy and liver disease associated with clinically significant bleeding risk
* Patients with clinically significant bleeding or bleeding risk
* Patients who underwent artificial heart valve replacement requiring anticoagulant administration
* Patients with pulmonary embolism who are hemodynamically unstable or require thrombolysis or pulmonary embolization.
* Pregnant and lactating women

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gwon, Jun Gyo

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Korea university anam hospital

Seoul, Non US/Canada, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jun Gyo Gwon, MD. PhD.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KoreaUAnamH

Identifier Type: -

Identifier Source: org_study_id